Press Releases

Date Title and Summary
Toggle Summary First Accuray CyberKnife® M6™ System Installed in Missouri at Mercy Hospital St. Louis
SUNNYVALE, Calif. , Feb. 25, 2020 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife ® M6™ System in Missouri at their state-of-the-art
Toggle Summary Studies Support Use of the Accuray TomoTherapy® System for Advanced Rectal Cancer to Improve Treatment Efficacy and Reduce Side Effects
SUNNYVALE, Calif. , Feb. 5, 2020 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today that two new studies demonstrate the benefits of the TomoTherapy ® System  in the treatment of advanced rectal cancer. Radiotherapy, with or without chemotherapy, followed by surgery is the
Toggle Summary Accuray Reports Fiscal 2020 Second Quarter Financial Results
SUNNYVALE, Calif. , Jan. 28, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the second quarter of fiscal 2020 ended December 31, 2019 . Recent Company Highlights Gross orders of $98.6 million , including 11 orders from China Net orders of $89.9
Toggle Summary Accuray To Report Fiscal 2020 Second Quarter Financial Results on January 28, 2020
SUNNYVALE, Calif. , Jan. 16, 2020 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) will report results for its second quarter ended December 31, 2019 on Tuesday, January 28, 2020 after the market close. Management will host a conference call to review the results at 1:30 p.m. PT / 4:30 p.m.
Toggle Summary Accuray To Discuss Revenue Growth Expectations for the Next Three Fiscal Years at the JP Morgan Healthcare Conference
Company to present on Wednesday, January 15, 2020 at 10 am PT / 1 pm ET SUNNYVALE, Calif. , Jan. 13, 2020 /PRNewswire/ --  Accuray Incorporated (Nasdaq: ARAY) will be discussing its business and revenue growth expectations for the next three fiscal years at the JP Morgan Healthcare Conference on
Toggle Summary Accuray CyberKnife® System Provides Excellent Disease Control for Men with Recurrent Prostate Cancer, a Medical Condition with Few Viable Treatment Options
SUNNYVALE, Calif. , Jan. 8, 2020 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today data from a prospective study which showed that at five years, stereotactic body radiation therapy (SBRT) administered with the CyberKnife ® System provided excellent disease control with low rates
Toggle Summary Accuray to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 15, 2020
SUNNYVALE, Calif. , Jan. 6, 2020 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that Joshua H. Levine , president and chief executive officer, will present at the 38 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 10:00 a.m. PT .
Toggle Summary Timpanogos Cancer Services First in Utah to Offer Precise and Accurate Radiation Treatments with the Accuray Radixact® System
System is Designed to Improve Treatment Results, Minimize Treatment Impact on Patients' Quality of Life SUNNYVALE, Calif. , Dec. 12, 2019 /PRNewswire/ -- Timpanogos Cancer Services made history in Utah recently with the installation of the state's first Radixact ® System , the next-generation
Toggle Summary Stanford University Medical Center to Acquire Second Accuray CyberKnife® M6™ System
New System will be Used to Treat Diseases in the Brain and Base of the Skull SUNNYVALE, Calif. , Dec. 4, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Stanford University Medical Center has selected a second CyberKnife ® M6™ System to expand access to precise
Toggle Summary Accuray Incorporated Reports Inducement Awards Under NASDAQ Listing Rules
SUNNYVALE, Calif. , Nov. 6, 2019 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Stock Market Rules, equity inducement awards to Suzanne Winter , the company's new Senior Vice President, Chief Commercial Officer.  As a material inducement to Ms.

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at and on the SEC's website at